These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30295803)
1. Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. Pasipanodya EC; Jain S; Sun X; Blumenthal J; Ellorin E; Corado K; Dube MP; Daar ES; Morris SR; Moore DJ; J Infect Dis; 2018 Oct; 218(10):1551-1559. PubMed ID: 30295803 [TBL] [Abstract][Full Text] [Related]
2. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J; BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230 [TBL] [Abstract][Full Text] [Related]
3. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Liu AY; Vittinghoff E; von Felten P; Rivet Amico K; Anderson PL; Lester R; Andrew E; Estes I; Serrano P; Brothers J; Buchbinder S; Hosek S; Fuchs JD Clin Infect Dis; 2019 May; 68(12):2010-2017. PubMed ID: 30239620 [TBL] [Abstract][Full Text] [Related]
4. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Moore DJ; Jain S; Dubé MP; Daar ES; Sun X; Young J; Corado K; Ellorin E; Milam J; Collins D; Blumenthal J; Best BM; Anderson P; Haubrich R; Morris SR Clin Infect Dis; 2018 May; 66(10):1566-1572. PubMed ID: 29228144 [TBL] [Abstract][Full Text] [Related]
5. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG; Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098 [TBL] [Abstract][Full Text] [Related]
6. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
7. A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. Fuchs JD; Stojanovski K; Vittinghoff E; McMahan VM; Hosek SG; Amico KR; Kouyate A; Gilmore HJ; Buchbinder SP; Lester RT; Grant RM; Liu AY AIDS Patient Care STDS; 2018 Mar; 32(3):104-111. PubMed ID: 29565183 [TBL] [Abstract][Full Text] [Related]
8. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
10. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM; Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029 [TBL] [Abstract][Full Text] [Related]
11. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM; Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Daily Text Messaging to Support Adherence to HIV Pre-Exposure Prophylaxis (PrEP) among Stimulant-Using Men Who Have Sex with Men. Serrano VB; Moore DJ; Morris S; Tang B; Liao A; Hoenigl M; Montoya JL Subst Use Misuse; 2023; 58(3):465-469. PubMed ID: 36659873 [No Abstract] [Full Text] [Related]
13. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
14. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877 [TBL] [Abstract][Full Text] [Related]
15. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B; AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400 [TBL] [Abstract][Full Text] [Related]
16. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
17. Pilot Randomized Controlled Trial of Game Plan for PrEP: A Brief, Web and Text Message Intervention to Help Sexual Minority Men Adhere to PrEP and Reduce Their Alcohol Use. Wray TB; Chan PA; Kahler CW; Ocean EMS; Nittas V AIDS Behav; 2024 Apr; 28(4):1356-1369. PubMed ID: 37971613 [TBL] [Abstract][Full Text] [Related]
18. Maximizing the Benefits of HIV Preexposure Prophylaxis. Buchbinder SP Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539 [TBL] [Abstract][Full Text] [Related]
19. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K; Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265 [TBL] [Abstract][Full Text] [Related]
20. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention. Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM; Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]